Baird Maintains Outperform on Haemonetics, Raises Price Target to $119

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $96 to $119.